Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PF-07104091 |
Synonyms | |
Therapy Description |
PF-07104091 inhibits CDK2, which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-07104091 | PF 07104091|PF07104091 | CDK2 Inhibitor 31 | PF-07104091 inhibits CDK2, which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04553133 | Phase II | PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 | PF-07104091 as a Single Agent and in Combination Therapy | Active, not recruiting | USA | BGR | ARG | 3 |